Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Kura Oncology (KURA) Income from Continuing Operations (2024 - 2025)

Kura Oncology (KURA) has disclosed Income from Continuing Operations for 2 consecutive years, with 80999000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Income from Continuing Operations fell 370.95% to 80999000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was 278440000.0, a 61.92% decrease, with the full-year FY2025 number at 278666000.0, down 60.17% from a year prior.
  • Income from Continuing Operations was 80999000.0 for Q4 2025 at Kura Oncology, down from 74116000.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 17199000.0 in Q4 2024 to a low of 80999000.0 in Q4 2025.